Traditional imaging techniques, which typically rely on the experience of the analyst, are made much more effective when combined with molecular markers such as MGMT gene promoter methylation, IDH1 and IDH2 gene mutations, and 1p/19q codeletion. Comprehending the many molecular indicators associated with juvenile glioblastoma is crucial in order to customize treatment approaches to the distinct features of each patient’s tumor. The gene discussed is IDH2; the disease is neoplasm.